



MEDICAL POLICY STATEMENT

Georgia Medicaid

| Policy Name & Number | Date Effective |
|---|----------------|
| Breast Reduction Surgery-GA MCD-MM-0253 | 07/01/2024 |
| Policy Type | |
| MEDICAL | |

Medical Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

| | |
|----------------------------------|---|
| A. Subject | 2 |
| B. Background | 2 |
| C. Definitions | 2 |
| D. Policy | 3 |
| E. Conditions of Coverage | 6 |
| F. Related Policies/Rules | 6 |
| G. Review/Revision History | 7 |
| H. References | 7 |

A. Subject

Breast Reduction Surgery

B. Background

Gynecomastia is the benign proliferation, either unilateral or bilateral, of glandular tissue of the breast in males. This develops most often in the setting of altered estrogen/androgen balance or increased sensitivity of breast tissue to estrogen. Causes may include androgen deficiency (eg, treatments for prostate carcinoma), congenital disorders (eg, Klinefelter Syndrome (47,XXY)), medications (eg, estrogen replacement therapy, calcium channel blockers, cimetidine, phenothiazines, spironolactone, theophylline, highly active antiretroviral therapy), chronic medical conditions (eg, cirrhosis, chronic kidney disease), tumors (eg, adrenal or testicular), or endocrine disorders (eg, hyperthyroidism). As a result of this hormonal imbalance, medication therapy may be offered in the treatment of gynecomastia (ie, anti-estrogens, androgens, or aromatase inhibitors).

Women diagnosed with macromastia (or excessively large breasts) seeking breast reduction typically present with complaints of a feeling of heaviness, chronic pain, and tension in the neck, shoulders, and upper back. Macromastia commonly causes permanent grooving and ulceration of the shoulder following years of wearing support bras to try to minimize symptoms. The physical and psychological symptoms of macromastia can significantly and negatively impact an individual's life and should be taken into consideration when evaluating surgical intervention.

Reduction mammoplasty is a surgical procedure that reduces the weight and volume of the breast. As much as two to five pounds of excess breast tissue is routinely removed during a reduction mammoplasty. Indications for surgery include chronic pain and skin symptoms, neuropathy, breast discomfort, physical impairment, and psychological symptoms that can be associated with poor self-esteem and loss of desire to engage in activities.

C. Definitions

- **Body Surface Area (BSA)** – A metric used for physiologic measurements, pharmacologic dosing, as well as for therapeutic calculations, including the Schnur Sliding Scale for breast reduction surgery.
- **Cosmetic Procedures** – Procedures that correct an anatomical congenital anomaly without improving or restoring physiologic function are considered cosmetic procedures.
- **Functional/Physical or Physiological Impairment** – Impairment causes deviation from the normal function of a tissue or organ. This results in a significantly limited, impaired, or delayed capacity to move and coordinate actions, or perform physical activities exhibited by difficulties in one or more of the following areas: physical and motor tasks, independent movement, and performing basic life functions.

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

- **Intertriginous Rash** – Dermatitis occurring between juxtaposed folds of skin, caused by retention of moisture and warmth and providing an environment favoring overgrowth of normal skin micro-organisms.
- **Kyphosis** – Over-curvature of the thoracic vertebrae (upper back) associated with degenerative diseases, such as arthritis, developmental problems, or with osteoporotic compression fractures of vertebral bodies.
- **Macromastia (Breast Hypertrophy)** – An increase in the volume and weight of breast tissue relative to the general body habitus.
- **Persistent Pubertal Gynecomastia** – The persistence of breast enlargement following the end of puberty and occasionally lasting into adulthood.
- **Postpubertal Male** – Tanner stage V milestones have been completed.
- **Precocious Puberty in Males** – Onset of secondary sexual characteristics before the age of nine.
- **Pseudo-Gynecomastia** – Enlargement of the breast due to fat deposition (without glandular involvement), typically occurring in the setting of obesity.
- **Pubertal Gynecomastia** – A benign process occurring most commonly between the ages of 10 to 14, typically followed by regression in most cases.
- **Pubertal Male** – Onset of secondary sexual characteristics that is measured using the Tanner stages; puberty includes stages II, III, and IV.
- **Symptomatic Breast Hypertrophy** – A syndrome of persistent neck and shoulder pain, shoulder grooving from brassiere straps, chronic intertriginous rash of the inframammary fold, and/or frequent episodes of headache, backache, and upper extremity neuropathies caused by breast tissue volume and weight exceeding normal proportions.
- **Schnur Sliding Scale** – An evaluation method promoted for use in calculating the amount of breast tissue to be removed in reduction mammoplasty (Appendix A).
- **Tanner Stages** – Sexual maturity rating of secondary sexual characteristics.

D. Policy

- I. CareSource considers breast reduction surgery for gynecomastia medically necessary when **ALL** of the following clinical criteria are met:
 - A. Member is at least 18 years old or older (or 18 months after the end of puberty, whichever occurs last).
 - B. The tissue being removed is glandular breast tissues and not the result of obesity, adolescence, or reversible effects of drug treatment that can be discontinued. Documentation should be maintained in the medical record.
 - C. Documentation indicates any condition associated with gynecomastia (eg, androgen deficiency, chronic liver disease that causes decreased androgen availability, Klinefelter syndrome, adrenal tumors that cause androgen deficiency or increased secretion of estrogen, brain tumors that cause androgen deficiency, testicular tumors causing androgen deficiency or tumor secretion of estrogen, or endocrine disorders such as hyperthyroidism).
 - D. Documentation supports that breast malignancy was ruled out.
 - E. The use of liposuction to perform breast reduction is considered investigational

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

and is noncovered.

- II. CareSource considers breast reduction surgery for macromastia medically necessary when **ALL** of the following clinical criteria are met:
- A. Member is 18 years or older, or under 18 years with documented evidence that breasts have finished growing for a minimum of one year (parental/guardian consent is required for members under age 18).
 - B. Breast size interferes with activities of daily living, as indicated by 1 or more of the following:
 - 1. arm numbness consistent with brachial plexus compression syndrome
 - 2. cervical pain
 - 3. chronic breast pain
 - 4. headaches
 - 5. nipple position greater than 21 cm below suprasternal notch
 - 6. persistent redness and erythema (intertrigo) below breasts
 - 7. restriction of physical activity
 - 8. severe bra strap grooving or ulceration of shoulder
 - 9. shoulder pain
 - 10. thoracic kyphosis
 - 11. upper or lower back pain
 - C. Preoperative evaluation by surgeon concludes that the amount of breast tissue to be removed (by mass or volume) will provide a reasonable expectation of symptomatic relief.
 - D. No evidence of breast cancer
 - 1. As evidenced by results of a physical exam completed by a physician within the last year if under 40.
 - 2. Women 40 to 54 years of age or older must have documentation of a mammogram negative for cancer performed within the year prior to the date of the planned breast reduction surgery.
 - 3. Women 55 years of age and older may switch to mammograms every 2 years.
- III. Breast reduction surgery following mastectomy to achieve symmetry is covered as part of the *Women's Health and Cancer Rights Act (WHCRA)*. Please refer to the CareSource Medical policy titled *Breast Reconstruction Post Mastectomy* for additional information.
- IV. Schnur Sliding Scale
- The Schnur Sliding Scale is an evaluation tool used to determine the appropriate volume of tissue to be removed relative to a member's total body surface area (BSA).
- A. This estimation can be instrumental in determining whether breast reduction surgery is being planned for cosmetic reasons or as a medically necessary procedure. In a survey of plastic surgeons utilizing this scale, Schnur, et al (1991) determined that a member whose removed breast weight was above the 22nd percentile were likely to receive the procedure for medical reasons.

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

- B. The weight of tissue to be removed from each breast must be above the 22nd percentile on the Schnur Sliding Scale (Appendix A below) based on the individual's BSA.
- C. The BSA in meters squared (m²) is calculated using the Mosteller formula as follows:
 1. Square root of the result of height (inches) multiplied by weight (lbs.) and divided by 3131.

Appendix A: Schnur Sliding Scale

| Body Surface Area and Minimum Requirement for Breast Tissue Removal | |
|---|--|
| Body Surface Area (m²) | Grams per Breast of Minimum Breast Tissue to be Removed |
| 1.350-1.374 | 199 |
| 1.375-1.399 | 208 |
| 1.400-1.424 | 218 |
| 1.425-1.449 | 227 |
| 1.450-1.474 | 238 |
| 1.475-1.499 | 249 |
| 1.500-1.524 | 260 |
| 1.525-1.549 | 272 |
| 1.550-1.574 | 284 |
| 1.575-1.599 | 297 |
| 1.600-1.624 | 310 |
| 1.625-1.649 | 324 |
| 1.650-1.674 | 338 |
| 1.675-1.699 | 354 |
| 1.700-1.724 | 370 |
| 1.725-1.749 | 386 |
| 1.750-1.774 | 404 |
| 1.775-1.799 | 422 |
| 1.800-1.824 | 441 |
| 1.825-1.849 | 461 |
| 1.850-1.874 | 482 |
| 1.875-1.899 | 504 |
| 1.900-1.924 | 527 |
| 1.925-1.949 | 550 |

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

| | |
|------------------|------|
| 1.950-1.974 | 575 |
| 1.975-1.999 | 601 |
| 2.000-2.024 | 628 |
| 2.025-2.049 | 657 |
| 2.050-2.074 | 687 |
| 2.075-2.099 | 717 |
| 2.100-2.124 | 750 |
| 2.125-2.149 | 784 |
| 2.150-2.174 | 819 |
| 2.175-2.199 | 856 |
| 2.200-2.224 | 895 |
| 2.225-2.249 | 935 |
| 2.250-2.274 | 978 |
| 2.275-2.299 | 1022 |
| 2.300-2.324 | 1068 |
| 2.325-2.349 | 1117 |
| 2.350-2.374 | 1167 |
| 2.375-2.399 | 1219 |
| 2.400-2.424 | 1275 |
| 2.425-2.449 | 1333 |
| 2.450-2.474 | 1393 |
| 2.475-2.499 | 1455 |
| 2.500-2.524 | 1522 |
| 2.525-2.549 | 1590 |
| 2.550 or greater | 1662 |

E. Conditions of Coverage

N/A

F. Related Policies/Rules

Breast Reconstruction Surgery

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

G. Review/Revision History

| DATE | | ACTION |
|-----------------------|------------|---|
| Date Issued | 04/02/2019 | |
| Date Revised | 04/15/2020 | Annual Update: Update to MCG Health Clinical Indications; addition of Related Policies. |
| | 03/17/2021 | |
| | 03/16/2022 | Added male breast reduction surgery criteria. Updated references. Approved at PGC. |
| | 03/15/2023 | Revised D.I, D.I.A., D.II. and D.II.A. Updated references. Approved at Committee |
| | 06/21/2023 | Removed II.C. Updated references. Approved at Committee. |
| | 02/28/2024 | Revision: expanded policy to cover members under 18 years of age, removed definitions, and updated references. Approved at Committee. |
| Date Effective | 07/01/2024 | |
| Date Archived | | |

H. References

1. Biro FM, Chan YM. Normal puberty. UpToDate. Updated October 25, 2023. Accessed February 16, 2024. www.uptodate.com
2. Braunstein GD, Anawalt BD. Clinical features, diagnosis, and evaluation of gynecomastia in adults. UpToDate. Updated April 26, 2023. Accessed February 16, 2024. www.uptodate.com
3. Braunstein GD, Anawalt BD. Management of gynecomastia. UpToDate. Updated May 10, 2021. Accessed February 16, 2024. www.uptodate.com
4. Briefing paper: plastic surgery for teenagers. American Society of Plastic Surgeons. Accessed February 16, 2024. www.plasticsurgery.org
5. Fagerlund A, Lewin R, Ruffolo G, et al. Gynecomastia: a systematic review. *J Plast Surg Hand Surg.* 2015;49(6):311-318. doi:10.3109/2000656X.2015.1053398
6. Guliyeva G, Cheung JY, Avila FR, et al. Effect of reduction mammoplasty on pulmonary function tests: a systematic review. *Ann Plast Surg.* 2021;87(6):694-698. doi:10.1097/SAP.0000000000002834
7. Hansen J, Chang S. Overview of breast reduction. UpToDate. Updated April 19, 2023. Accessed February 16, 2024. www.uptodate.com
8. Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines- gynecomastia evaluation and management. *Andrology.* 2019;7(6):778-793. doi:10.1111/andr.12636
9. Kimia R, Magee L, Caplan HS, et al. Trends in insurance coverage for adolescent reduction mammoplasty. *Am J Surg.* 2022;224(4):1068-1073. doi:10.1016/j.amjsurg.2022.07.030
10. Knox JA, Nelson DA, Latham KP, et al. Objective effects of breast reduction surgery on physical fitness. *Ann Plast Surg.* 2018;80(1):14-17. doi:10.1097/SAP.0000000000001167

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

11. Lewin R, Liden M, Lundberg J, et al. Prospective evaluation of health after breast reduction surgery using the Breast-Q, Short-Form 36, Breast-Related Symptoms Questionnaire, and Modified Breast Evaluation Form. *Ann Plast Surg.* 2019;83(2):143-151. doi:10.1097/SAP.0000000000001849
12. Morrison KA, Vernon R, Choi M, et al. Quantifying surgical complications for reduction mammoplasty in adolescents. *Plast Reconstr Surg.* 2023;151(3):376e-383e. doi:10.1097/PRS.00000000000009905
13. Nuzzi LC, Firriolo JM, Pike CM, et al. The effect of reduction mammoplasty on quality of life in adolescents with macromastia. *Pediatrics.* 2017;140(5):e20171103. doi:10.1542/peds.2017-1103
14. Nuzzi LC, Pramanick T, Walsh LR, et al. Optimal timing for reduction mammoplasty in adolescents. *Plast Reconstr Surg.* 2020;146(6):1213-1220. doi:10.1097/PRS.00000000000007325
15. Patel K, Corcoran J. Breast reduction surgery in adolescents. *Pediatr Ann.* 2023;52(1):e31-e35. doi:10.3928/19382359-20221114-06
16. Perdakis G, Dillingham C, Boukovalas S, et al. American Society of Plastic Surgeons evidence-based clinical practice guideline revision: reduction mammoplasty. *Plast Reconstr Surg.* 2022;149(3):392e-409e. doi:10.1097/PRS.00000000000008860
17. Perez-Panzano E, Gascon-Catalan A, Sousa-Dominguez R, et al. Reduction mammoplasty improves levels of anxiety, depression and body image satisfaction in patients with symptomatic macromastia in the short and long term. *J Psychosom Obstet Gynaecol.* 2017;38(4):268-275. doi:10.1080/0167482X.2016.1270936
18. Reduction mammoplasty. MCG. 28th ed draft. Updated December 12, 2023. Accessed February 16, 2024. www.careweb.careguidelines.com
19. Taylor SA. Gynecomastia in children and adolescents. UpToDate. Updated June 10, 2022. Accessed February 16, 2024. www.uptodate.com
20. Women's Health and Cancer Rights Act (WHCRA). Centers for Medicare and Medicaid Services. Accessed February 16, 2024. www.cms.gov
21. Xia TY, Scomacao I, Duraes E, Cakmakoglu C, Schwarz G. Aesthetic, quality-of-life, and clinical outcomes after inferior pedicle oncoplastic reduction mammoplasty. *Aesthetic Plast Surg.* 2023;47(3):905-911. doi:10.1007/s00266-023-03257-7
22. Zeiderman MR, Kelishadi SS, Tutela JP, et al. Reduction mammoplasty: intraoperative weight versus pathology weight and its implications. *Eplasty.* 2017;17:e32. Accessed February 16, 2024. www.pubmed.ncbi.nlm.nih.gov